Herb-drug interactions involving drug metabolizing enzymes and transporters

Current Drug Metabolism

Volumn 12, Issue 9, 2011, Pages 835-849

  Liu, Chang Xiao ^a   Yi, Xiu Lin ^a   Si, Duan Yun ^a   Xiao, Xue Feng ^a,b   He, Xin ^b   Li, Ya Zhuo ^a  

^a TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Drug drug interaction; Herb drug interactions; Herbal medicines; Metabolizing enzymes; Transporter

Indexed keywords

AMITRIPTYLINE; ANGELICA EXTRACT; COUMARIN; CURCUMIN; CYCLOSPORIN; DEXTROMETHORPHAN; DIGOXIN; DILTIAZEM; DOXORUBICIN; EMODIN; FUROCOUMARIN; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCYRRHIZA URALENSIS EXTRACT; HERBACEOUS AGENT; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; KAEMPFEROL; LIGNAN; QUERCETIN; SCOPOLETIN; SILYBUM MARIANUM EXTRACT; SILYMARIN; SITOGLUSIDE; TACROLIMUS; TETRANDRINE; UNINDEXED DRUG; WARFARIN;

DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME INDUCTION; ENZYME INHIBITION; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; NONHUMAN; REVIEW;

EID: 80053487247     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011797470083     Document Type: Review

References (134)

1. Zhou, L.; Huang, X.; Fu, C.; Song, H.; Zhou, X.F.. Study on Regularity of using Compound Herbal Formulae in Treating Coronary Heart Disease. Shanghai J. Radmon. Chin. Med., 2006, 39(2), 64-65.
2. Qu, Y.Z.; Gao, G.D. Therapeutical development og ligustrozing and its combined medication on cerebral ischemia-reperfusion. Chin. J. Clin. Rehabilit., 2004, 8(19), 3862-63.
3. He, S.M.; Niu, Y.J. Combination therapy clinical study of antiulcer treatment. Guangxi Tradit Med J., 2001, 24(6), 337-338.
4. Liu, Y.H.; Hou, A.C.; Zhao, G.C.; Wang, F.L.; Wu, S.G-In vitro inhibition of respiratory syncytia virus with combined ribavirin and an oral preparation of traditional Chinese medicine. Chin. J. Exp. Clin. Virol., 2003, 17(2), 187-188.
5. Qiu, W.; Liu, C.X.; Ju, Y.; Zhang, H.Y. Pharmacokinetic Interaction of Plant Preparations with Chemical Drugs. Chin. J. Nat .Med. Mar., 2010, 8 (2), 137-144.
6. Sparreboom, A.; Cox, M.C.; Acharya, M.R.; Figg, W.D.. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J. Clin. Oncol., 2004, 22(12), 2489-2503. (Pubitemid 41115408)
7. Zhou, S.F.; Zhou, Z.W.; Li, C.G.; et al. Identification of drugs that interact with herbs in drug development. Drug Discov. Today, 2007, 12, 664-673.
8. Levêque, D.; Lemachatti, J.; Nivoix, Y.; Coliat, P.; Santucci, R.; Ubeaud-Séquier. G.; Beretz, L.; Vinzio, S. Mechanisms of pharmacokinetic drug-drug interactions. Rev. Med. Interne., 2010, 1(2), 170-179.
9. Frank, R.; Meier, P.J,; Turina, M.; Lüscher, T, F.; Georg N.. Acute heart transplant rejection due to Saint John's wort. The Lancet, 2000, 355, 548-549. (Pubitemid 30088678)
10. Pal, D.; Mitra, A.K. MDR- and CYP-3A4-mediated drug-herbal interactions. Life Sci., 2006, 78:2131-2145.
11. He, N.; Edeki, T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am. J. Ther., 2004, 11(3), 206-212.
12. M. Joyeux', A. Lobstein', R. Anton', and F. MortierXJ. Comparative Antilipoperoxidant, Antinecrotic and Scavenging Properties of Terpenes and Biflavones from Ginkgo and some Flavonoids. Planta Mcd., 1995, 61: 126-129.
13. Chang, T.K.; Chen, J.; Benetton, S.A. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab. Dispos., 2002, 30(4), 378-384. (Pubitemid 34263821)
14. Xu, Z.Y.; Li, D.R. MDR in cancer chemotherpy. Chin. J. Cancer Res., 2006, 15(6), 380-385.
15. Mao, X.Q.; Xie H.T.; Zhou, H.H. MDR Proteins and CYP3A4 in herb-drug interactions. Chin. Clin. Pharmaco.l Ther., 2007, 12 (7), 728-734.
16. Wang, B.L.; Li, Y. Herb-drug interaction and mechanism in pharmacokinetics. Chin. J. Pharmacol. Toxicol., 2008, 22 (3), 237-240.
17. Zeddulika, O.; Jurica, J.; Sulcova, A. The inhibitory effect of quercetin on rat hepatal CYP2D2. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 56.
18. Li, Q.; Jiao, J.J.; Han X.W.; Lou, J.S. Simultaeous evaluation of influence of Scutellaria baicalensis Georgi on CYP450 by cocktail probe drugs. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 60.
19. He, X.; Feng, S.; Wang, Y.F.; Li, C.; Hou, J.P.; Martey, O.N.K.; Liu, C.X. Herb-drug interaction: Effect of isopelustrin on the metabolism and pharmacokinetics of tetramethylpyrazine by in vivo and in vitro methods. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 85.
20. Zhang, Y.Y.; Yang, L. Deoxyschizandrin could attenuate cytochrome P450 3A4-mediated bioactivation of gomisin A in human liver microsomes. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 104.
21. Ismail, S.; Hanap, N.A.; Azizi, J.; Mansor, S.M.; Mahumud, R. Inhibition of human cytochrome P450 isoforms by Mitragyna speciosa extracts. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 106.
22. Stilinovic, N.; Sederino, R.; Raskovic, A.; Vukmirovic, S.; Paut, M. Can sil ymarin prevent cardio and hepatotoxicity induced with doxorubicin? The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 130.
23. Hu, Y.; Xin H.; Li, N.; Yang L. Deoxyscizandrin improved the absorption of P-glycosprotein (P-gp) subsytrate drugs in human intestinal Caco-2 cells. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 130.
24. Wang, X.A.; Wo, S.; Zuo, Z. Mechanistic study on the metabolism inhibition of oseltamivir by herbal components. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 132.
25. Bi, H.C.; Qin X.L.; Chen X.; Huang, M. Mechanistic understanding of the effects of 6 schisandrins on the absorption and fisrt-pass intestinal and hepatic metabolism of tacrolimus. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 132-133.
26. Qi, X.Y.; Liang, S.C.; Ge, G.B.; Fang, Z.Z.; Yang, L. inhibition of human liver cytochrome P450 2C8 and 3A4 by sanguinarine. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 107.
27. Sen, A.; Akca, H.; Celik, G. Dietary aromatase inhibitors in human non-small cell lung cancer. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 126.
28. Mollik A.H. Living knowledge of the healing plants: Ethnototherapy in the local peoplr, Santal and Orao ethnic groups from Rangpur district of Bangladesh. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 128.
29. Arslan, S.; Ozgun, O.; Sen, A. Differntial effects of cytolamen extract on P450 gene expression. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 131.
30. Zhang, G.L.; Li T.Y.; Wang X.; Wang S.M.; Li, D.; Zhao, X. Effect of naringenin on metabolic activity of cytochrome p450 1A2 and 3A in BCG immune liver injury in mice. The 9th International ISSX Meeting: Program & Abstracts., September 4-8, Istanbul, Turkey, 2010, 131.
31. Mollik A.H. Local administration of medicinal plants in treating neurogas- troentrogy and motility disorders: Results from a crossspectional study in Khulna district of Bangladesh. The 9th International ISSX Meeting: Program & Abstracts., Istanbul, Turkey, September 4-8, 2010, 131-132.
32. Markowitz, J.S.; DeVane, C.L. The emerging recognition of herbdrug interactions with a focus on St. John's wort (Hypericum perforatum). Psychopharmacol. Bull., 2001, 35, 53-64.
33. Durr, D.; Stieger, B.; Kullak-Ublick, G.A.; Rentsch, K.M.; Steinert, H.C.; Meier, P.J.; Fattinger, K. St John's wort induces intestinal P-glyeoprotein/MDR1 and intestinal and hepatic CYP3A4. C1in. Pharmacol. Ther., 2000, 68, 598-604. (Pubitemid 32059985)
34. Henney, J.E. Risk of drug interactions with St. John's wort. J. Am. Med. Assoc., 2000, 283, 1679.
35. Piscitelli, S.C.; Burstein, A.H.; Chaitt, D,; Alfaro, R.M.; Falloon, J. Indinavir concentrations and St John's Wort. Lancet, 2000, 355, 547-548. (Pubitemid 30088677)
36. Unger, M. Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance. Wien. Med. Wochenschr., 2010, 160(21-22), 571-577.
37. Yang, A.K.; He, S.M.; Liu, L.; Liu, J.P.; Wei, M.Q.; Zhou, S.F. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr. Med. Chem., 2010, 17(16), 1635-1678.
38. Lee, L.S.; Andrade, A.S.; Flexner, C. Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin. Infect. Dis., 2006, 43(8), 1052-1059. (Pubitemid 44631108)
39. Venkataramanan, R.; Komoroski, B.; Strom, S. In vitro and in vivo assessment of herb drug interactions. Life Sci., 2006, 78(18), 2105-15.
40. Yin, O.Q.; Tomlinson, B.; Waye, M.M. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics, 2004, 14(12), 841-850. (Pubitemid 40054339)
41. Ohnishi, N.; Kusuhara, M.; Yoshioka, M.; Kuroda, K.; Soga, A,.; Nishikawa, F.; Koishi,T.; Nakagawa, M.; Hori, S.; Matsumoto, T.; Yamashita, M.; Ohta, S.; Takara, K.; Yokoyama, T. Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol. Pharm. Bull., 2003, 26, 1315-1320. (Pubitemid 41656569)
42. Smith, M.; Lin, K.M.; Zheng, Y.P. An open trial of nifedipine-herb interactions: Nifedipine with St. John's wort, ginseng or Ginkgohiloha. Clin. Pharmacol. Ther., 2001, 69, 86.
43. Fan, L.; Tao, G.Y.; Wang, G.; Chen, Y.; Zhang, W.; He, Y.J.; Li, Q.; Lei, H.P.; Jiang, F.; Hu, D.L.; Huang, Y.F.; Zhou, H.H. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann. Pharmacother., 2009, 43(5), 944-949.
44. He, N.; Edeki, T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am. J. Ther., 2004, 11(3), 206-212.
45. Chang, T.K.; Chen, J.; Benetton, S.A. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab. Dispos., 2002, 30(4), 378-84. (Pubitemid 34263821)
46. Ioannides, C. Pharmacokinetics interactions between herbal remedies and medicinal drugs. Xenobiotica, 2002, 32(6):451-478. (Pubitemid 34743619)
47. Henderson, G.L.; Harkeym, R.; Gershwinm, M.E.; Hackman, R.M.; Stern, J.S.; Stresser, D.M. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci., 1999, 65: 209-214.
48. Kim, S.W.; Kwon, H.Y.; Chi, D.W.; Shim, J.H.; Park, J.D.; Lee, Y.H.; Pyo, S.; Rhee, D.K. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenosige Rg3. Biochem. Pharmacol., 2003, 65:75-82. (Pubitemid 35447841)
49. China Pharmacopoeia committee. China Pharmacopoeia, Beijing: People's Health Publishers, 2010, (1), 70-71.
50. Chan, K.; Lo, A.C.; Yeung, J.H.; Woo, K.S. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J. Pharm. Pharmacol., 1995, 47, 402-406.
51. Qiu, F.; Zhang, R.; Sun, J.; Jiye, A.; Hao, H.; Peng, Y.; Ai, H.; Wang, G. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab. Dispos., 2008, 36, 1308-1314. (Pubitemid 351929315)
52. Bano, G.; Raina, B.K.; Zutshi, U. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur. J. Clin. Pharmacol., 1991, 41, 615-617.
53. Benfield, P.; Clissold, S.P.; Brogden, R.N. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs, 1986, 31,376-429. (Pubitemid 16079570)
54. Li, F.; Cooper, S.F.; Côté, M. Determination of the enantiomers of metoprolol and its major acidic metabolite in human urine by highperformance liquid chromatogr- aphy with fluorescence detection. J. Chromatogr. B, 1995, 668, 67-75.
55. Tateishi, T.; Nakashima, H.; Shitou, T.; Kumagai, Y.; Ohashi, K.; Hosoda, S.; Ebihara, A. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur. J. Clin. Pharmacol., 1989, 36, 67-70. (Pubitemid 19052013)
56. Bauer, L.A.; Horn, J.R.; Maxon, M.S.; Easterling, T.R.; Shen, D.D.; Strandness, D.E.Jr. Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition. J. Clin. Pharmacol., 2000, 40, 533-543.
57. Werner, D.; Wuttke, H.; Fromm, M.F.; Schaefer, S.; Eschenhagen, T.; Brune, K.; Daniel, W.G.; Werne,r U. Effect of amiodarone on the plasma levels of metoprolol. Am. J. Cardiol., 2004, 94, 1319-1321. (Pubitemid 39469961)
58. Fukumoto, K.; Kobayashi, T.; Tachibana, K.; Kato, R.; Tanaka, K.; Komamura, K.; Kamakura, S.; Kitakaze, M.; Ueno, K. Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. Drug Metab. Pharmacokinet., 2006, 21, 501-505.
59. Wan, R.Z.; Zhou, M.J.; Liu, C.X. The effects of salvianolic acid B from radix salvia miltiorrhizae on the oral pharmacokinetics of metoprolol and metoprolol acid in rats. Phytother. Res., 2010, 24(6), 846-51.
60. Murthy, S.S.; Nelson, W.L.; Shen, D.D.; Power, J.M.; Cahill, C.M.; McLean, A.J. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Drug Metab. Dispos., 1991, 19, 1093-1100.
61. Boralli, V.B.; Coelho, E.B.; Lanchote, V.L. Influence of quinidine, cimetidine, and ketoconazole on the enantioselective pharmacokinetics and metabolism of metoprolol in rats. Chirality, 2009, 21(10), 886-93.
62. Ueng, Y.F.; Kuo, Y.H.; Wang, S.Y.; Lin, Y.L.; Chen, C.F. Induction of CYP1A by a diterpene quinine tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice. Life Sci., 2004, 74(7), 885-896.
63. Tang, J.C.; Zhang, J.N.; Wu, Y.T.; Li, Z.X.. Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong Hort. And Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother. Res., 2006, 20(12), 1046-1051.
64. Paolini, M. ; Pozzetti, L. ; Sapone, A. ; Cantelli-Forti, G. Effect of licorice and glycyrrhizin on murine liver CYP-dependent monoxygeases. Life Sci., 1998, 62, 571-582. (Pubitemid 28050076)
65. Mu, Y.; Zhang, J.; Zhang, S.; Zhou, H.H.; Toma, D.; Ren, S.; Huang, L.; Yaramus, M.; Baum, A.; Venkataramanan, R.; Xie, W. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J. Pharmacol. Exp. Ther., 2006, 316(3), 1369-1377. (Pubitemid 43345314)
66. Tsukamoto, S.; Aburatani, M.; Yoshida, T.; Yamashita, Y.; El- Beih, A.A.; Ohta, T. CYP3A4 inhibitors isolated from Licorice. Biol. Pharm. Bull., 2005, 28(10), 2000-2002. (Pubitemid 41437100)
67. Kent, U.M.; Aviram, M.; Rosenblat, M.; Hollenberg, P.F. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450 3A4, 2B6, and 2C9. Drug Metab. Dispos., 2002, 30(6), 709-715. (Pubitemid 34579106)
68. Ohnishi, N.; Yonekawa, Y.; Nakasako, S.; Nagasawa, K.; Yokoyama, T.; Yoshioka, M.; Kuroda, K. Studies on interactions between traditional herbal and Western medicines. I. Effects of Sho-seiryu-to on the pharmacokinetics of carbamazepine in rats. Biol. Pharm. Bull., 1999, 22(5), 527-31. (Pubitemid 29252229)
69. Chen, J.F.; Xu, P.; Zhu, S.Y.; Hu, Y.J.; Long, Z.H.; Li, H. Effect of licorice on carmazepine pharmacokinetics in rats. Chin. J. Clin. Pharmaco.l Ther., 2010, 15(9), 1046-1050.
70. Piscitelli, S.C.; Formentini, E.; Burstein, A.H.; Alfaro, R.; Jagannatha S.; Falloon, J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy. 2002, 22(5), 55l-556.
71. Lee, C.K.; Choi, J.S. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology, 2010, 85(6), 350-6.
72. Yi, S.; Cho, J.Y.; Lim, K.S.; Kim, K.P.; Kim, J.; Kim, B.H.; Hong, J.H.; Jang, I.J.; Shin, S.G.; Yu, K.S. Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on Cytochrome P450 activities in healthy volunteer. Basic Clin. Pharmacol. Toxicol., 2009, 32(4), 659-66.
73. Guo, L.Q.; Taniguchi, M.; Xiao, Y.Q.; Baba, K.; Ohta, T.; Yamazoe, Y.. Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P4503A activity. Jpn. J. Pharmacol., 2000, 82, 122-129. (Pubitemid 30153593)
74. Guo, L.Q.; Yamazoe, Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol. Sin., 2004, 25,129-136. (Pubitemid 38186159)
75. Zhang, S.G.; Wang, L.; Cao, Y.H. Herb-drug interactions. Internat. J. Pharmaceut. Res., 2006, 33(5), 369-371.
76. Gallicano, K.; Foster, B.; Choudhri, S. Effect of short-term administration of garlic supplements on single-dose ritonavir phammeokinetics in healthy volunteers. Br. J. Clin. Pharmacol., 2003, 55, 199-202. (Pubitemid 36237866)
77. Piscitelli, S.C.; Burstein, A.H.; Welden, N.; Gallicano, K.D.; Falloon, J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infec. Dis., 2002, 34, 234-238. (Pubitemid 34028358)
78. Neuman, M. Metabolic effects and drug interactions provoked by vegetables: grapefruit, St. John's wort and garlic. Presse. Med., 2002, 31, 1416-1422. (Pubitemid 36287767)
79. Gwilt, P.R.; Lear, C.L.; Tempero, M.A.; Birt, D.D.; Grandjean, A.C.; Ruddon, R.W.; Nagel, D.L. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol. Biomarkers Prev., 1994, 3(2), 155-160. (Pubitemid 24170059)
80. Hu, Z.; Yang, X.; Ho, P.C.; Chan, S.Y.; Heng, P.W.; Chan, E.; Duan, W.; Koh, H.L.; Zhou, S. Herb-drug interactions: a literature review. Drugs, 2005, 65(9), 1239-1282. (Pubitemid 41038418)
81. Lai, Y.; Sampson, K.E.; Stevens, J,C. Evaluation of drug transporter interactions in drug discovery and development. Comb. Chem. High Throughput Screen., 2010, 13(2), 112-34.
82. De Gregori, S.; De Gregori, M,.; Ranzani, G.N.; Borghesi, A.; Regazzi, M.; Stronati, M. Drug transporters and renal drug disposition in the newborn. J. Matern. Fetal. Neonatal. Med., 2009, 22 (Suppl 3), 31-37.
83. Franke, R.M.; Gardner, E.R.; Sparreboom, A. Pharmacogenetics of drug transporters. Curr. Pharm. Des., 2010, 16(2), 220-30.
84. Scherrmann, J.M. Transporters in absorption, distribution, and elimination. Chem. Biodivers., 2009, 6(11), 1933-1942.
85. Levêque, D.; Lemachatti, J.; Nivoix, Y.; Coliat, P.; Santucci, R.; Ubeaud-Séquier, G.; Beretz, L.; Vinzio, S. Mechanisms of pharmacokinetic drug-drug interactions. Rev. Med. Interne., 2010, 31(2), 170-179.
86. Mizuna, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of Drug Transporter Studies on Drug Discovery and Development. Pharmacol. Rev., 2003, 55:425-461. (Pubitemid 37013212)
87. Wacher, V.J.; Salphati, L.; Benet, L.Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev., 2001, 46, 89-102.
88. Zhang, Y.; Benet, L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet., 2001, 40, 159-168. (Pubitemid 32324448)
89. Passamonti, S.; Terdoslavich, M.; Franca, R.; Vanzo, A.; Tramer, F.; Braidot, E.; Petrussa, E.; Vianello, A. Bioavailability of flavonoids: a review of their membrane transport and the function of bilitranslocase in animal and plant organisms. Curr. Drug Metab., 2009, 10(4), 369-94.
90. Perloff, M.D.; von Moltke, L.L.; Stormer, E.; Shader, R.I.; Greenblatt, D.J. Saint John's wort an in vitro analysis of Pglycoprotein induction due to extended exposure. Br. J. Pharmacol., 2001, 134, 1601-1608. (Pubitemid 34038092)
91. Ruschitzka, F.; Meier, P.J.; Turina, M.; Lüscher, T.F.; Noll, G.. Acute heart transplant rejection due to Saint John's wort. Lancet, 2000, 355(9203), 548-549. (Pubitemid 30088678)
92. Breidenbach, T.; Kliem, V.; Burg, M.; Roadermacher, J.; Hoffmann, M.W.; Klempnauer, J. Profound drop of cyclosporine A whole blood trough levels caused by St. John's wort. Transplantation, 2000, 69, 2229-2230. (Pubitemid 30395071)
93. Li, H.; Jin, H.E.; Kim, W.; Han, Y.H.; Kim, D.D.; Chung, S.J.; Shim, C.K. Involvement of P-glycoprotein, multidrug resistence protein 2 and beast cancer resistance protein in the transport of belotecam and toptecam in Caco-2 cell and MDCK II cells. Pharm. Res., 2008, 25(11), 2601-12.
94. Sha, X.Y.; Fang, X.L.; Wu, Y.J. The in vitro kinetics of uptake, transport and efflux of 9-nitrocamptothecin in Caco-2 cell model. Acta Pharm. Sin., 2004, 39(10), 839-843.
95. Scherrmann, J.M. Transporters in absorption, distribution, and elimination. Chem. Biodivers., 2009, 6(11), 1933-1942.
96. Zhang, H.X.; Wang, L.S. Effect of genetic polymorphism on the activity of drug transporters and its clinical significance. J. Zhongnan University, 2008, 33(8), 765-769.
97. Grover, A.; Benet, L.Z. Effects of drug transporters on volume of distribution. AAPS J., 2009, 11(2), 250-261.
98. Patti, J.; Buddha, B.; Dey. S.; Pal, D.; Mitra, A.K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am. J. Ther., 2004, 11, 262-277.
99. Yan, T.H. Inhibition effect of Schisandra compounds on CYP3A4. Internation Medicine: TCM,. 2004, 26(2), 125.
100. Yoo, H.H.; Lee, M.; Lee, M.W.; Lim, S.Y.; Shin, J.; Kim, D.H. Effects of Schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2. Planta Med., 2007, 73(5), 444-450. (Pubitemid 46917459)
101. Anuchapreeda, S.; Leechanachai, P.; Smith, M.M.; Ambudkar, S.V.; Limtrakul, P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol., 2002, 64, 573-582.
102. Mizuna, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of Drug Transporter Studies on Drug Discovery and Development. Pharmacol. Rev., 2003, 55, 425-461. (Pubitemid 37013212)
103. Lin, J.H. Drug-drug interaction mediated by inhibition and induction of Pglycoprotein. Adv. Drug Deliv. Rev., 2003, 55, 53-81. (Pubitemid 36082882)
104. Muck, W.; Mai, I.; Fritsche, L.; Ochmann, K.; Rohde, G.; Unger, S.; Johne, A.; Bauer, S.; Budde, K.; Roots, I. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine- treated kidney transplant recipients. Clin. Pharmacol. Ther., 1999, 65, 251-261. (Pubitemid 29142931)
105. Shitara, Y.; Itoh, T.; Sato, H.; Li, A.P.; Sugiyama, Y. Inhibition of transportermediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther., 2003, 304, 610-616. (Pubitemid 36152336)
106. Wang, L.; He, K.; Maxwell, B.; Grossman, S.J.; Tremaine, L.M.; Humphreys, W.G.; Zhang, D. Tissue distribution and elimination of C-14 apixaban in rats. Drug Metab Dispos., 2010, Epub ahead of print, PMID: 21039335.
107. Marquez, B.; Van Bambeke, F. ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions. Curr. Drug Targets., 2010, Epub ahead of print, PMID: 21071521.
108. Feng, B.; LaPerle, J.L.; Chang, G.; Varma, M.V. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. Expert. Opin. Drug Metab. Toxicol., 2010, 6(8), 939-52.
109. Liao, M.; Raczynski, A.R.; Chen, M.; Chuang, B.C.; Zhu, Q.; Shipman, R.; Morrison, J.; Lee, D.; Lee, F.W.; Balani, S.K.; Xia, C.Q. Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-drug interactions. Drug Metab. Dispos., 2010, 38(9), 1612-22.
110. Zhang, S.G.; Wang, L.; Cao, Y.H. Herb-drug interactions. Internat. J. Pharmaceut. Res., 2006, 33(5), 369-371.
111. Venkatakrishnan, K.; Von, M.L.L.; Greenblatt, D.J. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol., 2001, 41(11), 1149-1179 (Pubitemid 32983216)
112. Yang, A.K.; He, S.M.; Liu, L.; Liu, J.P.; Wei, M.Q.; Zhou, S.F. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr. Med. Chem., 2010, 17(16), 1635-1678.
113. Zlokarnik, G.; Grootenhuis, P.D.; Watson, J.B. High throughput P450 inhibition screens in early drug discovery. Drug Disc. Today, 2005, 10(21), 1443-1450. (Pubitemid 41483873)
114. Lundahl, J.; Regårdh, C.G.; Edgar, B.; Johnsson, G.. Effects of grapefruit juice ingestion pharmacolcinetics and haemedynamics of intravenously and orally administered felodipine in healthy men. Eur. J. Clin. Pharmacol., 1997, 52(2), 139-145. (Pubitemid 27239599)
115. Ducharme, M.P.; Warbases, L.H.; Edwards, D.J. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther., 1995, 57(5), 485-491.
116. Westphal, K.; Weinbrenner, A.; Giessmann, T.; Stuhr, M.; Franke, G.; Zschiesche, M.; Oertel, R.; Terhaag, B.; Kroemer, H.K.; Siegmund, W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther., 2000, 68(1), 6-12. (Pubitemid 30609821)
117. Butina, D.; Segall, M.D.; Frankcombe, K. Predicting ADME properties in silico: methods and models. Drug Disc. Today, 2002, 7(11), S83-88. (Pubitemid 34603635)
118. Shih, H.; Pickwell, G.V.; Guenette, D.K.; Bilir, B.; Quattrochi, L.C. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum Exp Toxicol. 1999, 18(2), 95-105. (Pubitemid 29087950)
119. Liu, Z.J.; Fu, D.X.; Tang, G. FDA guidelines on drug interactions in 2006. Internat J Pharmaceut. Res., 2008, 35(1), 50-55.
120. Yi, X.L.; Si, D.Y.; Liu, C.X. Pharmacokinetics evaluation on applications of human drug transporter. Drug Evaluat. Res., 2010, 33(5), 341-346.
121. Colalto, C. Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment. Pharmacol. Res., 2010, 62(3), 207-227.
122. Tanigawara, Y.; Okamura, N.; Hirai, M.; Yasuhara, M.; Ueda, K.; Kioka, N.; Komano, T.; Hori, R. Transport of digoxin by human Pglycoprotein expressed in a porcine kidney epithelial cell oine (LLC-PK1). J. Pharmacol. Exp. Ther., 1992, 263(2), 840-845.
123. Song, J.; Liu, X.L.; Peng, W.X. P-gp and cell models in drug-drug interactions. Chinese Pharmacy, 2006, 17(15), 1183-1185.
124. Smit, J.W.; Schinkel, A.H.; Weert, B.; Meijer, D.K. Hepatobilary and intestinal clearance of amphiphilic actionic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br. J. Pharmacol. 1998, 124(2), 416-424. (Pubitemid 28248034)
125. Kawahara, M.; Sakata, A.; Miyashita, T.; Tamai, I,; Tsuji, A. Phsiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J. Pharm. Sci., 1999, 88, 1281-1287.
126. Tomlinson, B.; Hu, M.; Lee, V.W. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach? Mol. Nutr. Food Res., 2008, 52(7), 799-809.
127. Huang, S.M.; Lesko, L.J. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J. Clin. Pharmacol., 2004, 44(6), 559-69. (Pubitemid 38668017)
128. Kusuhara, H.; Sugiyama, Y. In vitro-in vivo Extrapolation of Transporter- mediated Clearance in the Liver and Kidney. Drug Metab. Pharmacokinet. 2009, 24 (1), 37-52.
129. Kanai, Y.; Endou, H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr. Drug Metab., 2001, 2, 339-354. (Pubitemid 33133979)
130. Kanai, Y.; Endou, H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J. Toxicol. Sci., 2003, 28, 1-17. (Pubitemid 36362466)
131. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H.; Shimada, N.; Chiba, K.; Ishizaki, T.; Green, C.E.; Charles A. Tyson, C,A.; Sugiyama, Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther., 1997, 73, 147-171. (Pubitemid 27191615)
132. Soars, M.G.; McGinnity, D.F.; Grime, K.; Riley, R.J. The pivotal role of hepatocytes in drug discovery. Chem. Biol. Interact., 2007, 168(1), 2-15. (Pubitemid 46661937)
133. Tabata, K.; Hamakawa, N.; Sanoh, S.; Terashita, S.; Teramura, T. Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research. Eur. J. Drug Metab. Pharmacokinet., 2009, 34(2), 117-128.
134. Johnson, T.N.; Boussery, K.; Rowland-Yeo, K.; Tucker, G;T; Rostami-Hodjegan. A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet., 2010, 49(3), 189-206.